Viewing Articles By Chris O’Toole

To many in and around the biotech and pharmaceutical industries the hot topic of the moment is the future of biogenerics in the US market. As the new administration undertakes an overhaul of the $2.5 trillion healthcare environment much of the focus is on drug costs and the increasing role of generics. But it is generally accepted that drug costs account for just 10% of total spending, so why all the attention? Well, more than most other constituents, biotech and pharma manufacturers continue to share a higher profile - not always positive - and much of their critics' focus emphasizes excess profits, poor disclosure, and aggressive lobbying. Biotech and pharma are easy targets for political snipers (and many would argue they make it too easy for them) and so must deal with the biogenerics issue sensitively.